Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction

Shock

Volumn 8, Issue 5, 1997, Pages 328-334

  Inthorn, Dietrich ^a   Hoffmann, Johannes N ^a   Hartl, Wolfgang H ^a   Mühlbayer, Dieter ^a   Jochum, Marianne ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BILIRUBIN;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; FEMALE; HUMAN; KIDNEY; LIVER; LUNG; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ADULT; AGED; ANTITHROMBIN III; BILIRUBIN; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; KIDNEY; LIVER; LUNG; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SEPSIS;

EID: 0031266015     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199711000-00003     Document Type: Article

References (31)

1. Bone RC: The pathogenesis of sepsis. Ann Int Med 115: 457-469, 1991.
2. Christman JW, Holden EP, Blackwell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 23:955-963, 1995.
3. Okamoto K, Takaki A, Takeda S, Katoh H, Ohsato K: Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: Determination of prothrombin fragment 1 + 2 and other markers. Haemostasis 22:17-24, 1992.
4. Okajima K, Uchiba M, Murakami K: Antithrombin replacement in DIC and MOF. In Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Berlin Heidelberg: Springer-Verlag, 1995, pp 457-464.
5. van der Poll T, van Deventer SJ, Buller HR, Sturk A, ten Cate JW: Comparison of the early dynamics of coagulation activation after injection of endotoxin and tumor necrosis factor in healthy humans. Prog Clin Biol Res 367:55-60, 1991.
6. Bone RC: Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Int Med 152:1381-1389, 1992.
7. Mammen EF: Perspectives for the future. Intensive Care Med 19(Suppl. 1):S29-S34, 1993.
8. van Deventer SJ, Buller HR, ten Cate JW: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520-2526, 1990.
9. Lo SK, Lai L, Cooper JA, Malik AB: Thrombin-induced generation of neutrophil activating factors in blood. Am J Pathol 130:22-32, 1988.
10. Tanaka T, Tsujinaka T, Kambayashi: Sepsis model with reproducible manifestations of multiple organ failure (MOF) and disseminated intravascular coagulation (DIC). Thromb Res 54:53-61, 1989.
11. Emerson TEJ, Fournel MA, Redens TB, Taylor FBJ: Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 87:27S-33S, 1989.
12. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-87, 1992.
13. Blauhut B, Kramar H, Vinazzer H, Bergmann H: Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 39:81-89, 1985.
14. Arregui LM, Moyes DG, Lipman J, Fatti LP: Comparison of disease severity scoring systems in septic shock. Crit Care Med 19:1165-1171, 1991.
15. Goris RJA, te Boekhorst TPA, Nuytinck JKS, Gimbrere JSF: Multipleorgan failure. Arch Surg 120:1109-1115, 1985.
16. Gilbert R, Cuchincloss JH, Kuppinger M, Thomas MV: Stability of the arterial/alveolar oxygen partial pressure ratio. Crit Care Med 7:267-272, 1979.
17. Marshall JC, Cook DJ, Christou N: Multiple organ dysfunction score: A reliable descriptor of complex clinical outcome. Crit Care Med 23:1638-1652, 1995.
18. Hellgren M, Egberg N, Eklund J: Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intens Care Med 10:23-28, 1984.
19. Opal SM: Clinical trials of novel therapeutic agents: Why did they fail? In Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Berlin Heidelberg: Springer-Verlag. 1995, pp 457-464.
20. Fourrier F, Chopin C, Huart JJ: Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888, 1993.
21. Taylor FBJ, Emerson TEJ, Jordan R, Chang AK, Blick KE: Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26:227-235, 1988.
22. Dickneite G, Paques EP: Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 69:98-102, 1993.
23. Albert J, Blomqvist H, Gardlund B: Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 36:745-752, 1992.
24. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K: Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 270: L921-L930, 1996.
25. Horie S, Ishii H, Kazama M: Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 59:895-904, 1990.
26. Hartl WH, Herndon DN, Wolfe RR: Kinin/prostaglandin system: Its therapeutic value in surgical stress. Crit Care Med 18:1167-1173, 1990.
27. Langley PG, Hughes RD, Forbes A, Keays R, Williams R: Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 17:326-331, 1993.
28. Mammen EF, Miyakawa T, Phillips TF: Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Hemost 11:373-383, 1985.
29. Okano K, Kokudo Y, Okajima K, et al: Protective effects of antithrombin III supplementation on warm ischemia and reperfusion injury in rat liver. World J Surg 20:1069-1075, 1996.
30. Reeve E: Steady state reactions between factors X, Xa, II, IIa, antithrombin III and α2 macroglobulin in thrombosis. Thromb Res 18:19-31, 1980.
31. Wilson RF, Farag A, Mammen EF, Fujii Y: Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients. Am Surg 55:450-456, 1989.